During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.79 million, with the beta value of the company hitting 0.85. At the end of the trading day, the stock’s price was $16.08, reflecting an intraday loss of -6.29% or -$1.08. The 52-week high for the RCUS share is $20.31, that puts it down -26.31 from that peak though still a striking 15.92% gain since the share price plummeted to a 52-week low of $13.52. The company’s market capitalization is $1.47B, and the average intraday trading volume over the past 10 days was 0.64 million shares, and the average trade volume was 738.06K shares over the past three months.
Arcus Biosciences Inc (RCUS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.64. RCUS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.2.
Arcus Biosciences Inc (NYSE:RCUS) trade information
Arcus Biosciences Inc (RCUS) registered a -6.29% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.29% in intraday trading to $16.08, hitting a weekly high. The stock’s 5-day price performance is -7.00%, and it has moved by -2.13% in 30 days. Based on these gigs, the overall price performance for the year is -6.73%. The short interest in Arcus Biosciences Inc (NYSE:RCUS) is 8.03 million shares and it means that shorts have 10.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $29, which implies an increase of 44.55% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $46 respectively. As a result, RCUS is trading at a discount of -186.07% off the target high and -24.38% off the low.
Arcus Biosciences Inc (RCUS) estimates and forecasts
Statistics show that Arcus Biosciences Inc has outperformed its competitors in share price, compared to the industry in which it operates. Arcus Biosciences Inc (RCUS) shares have gone down -5.24% during the last six months, with a year-to-date growth rate more than the industry average at 22.89% against 17.10. In the rating firms’ projections, revenue will increase 122.68% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 31.31M as predicted by 8 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 40.7M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 31M and 145M respectively. In this case, analysts expect current quarter sales to grow by 1.01% and then drop by -71.93% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.70%. While earnings are projected to return 19.56% in 2024, the next five years will return 7.80% per annum.
RCUS Dividends
Arcus Biosciences Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Arcus Biosciences Inc (NYSE:RCUS)’s Major holders
Arcus Biosciences Inc insiders own 40.60% of total outstanding shares while institutional holders control 60.10%, with the float percentage being 101.18%. BLACKROCK INC. is the largest shareholder of the company, while 270.0 institutions own stock in it. As of 2024-06-30, the company held over 9.76 million shares (or 11.3261% of all shares), a total value of $148.69 million in shares.
The next largest institutional holding, with 5.26 million shares, is of VANGUARD GROUP INC’s that is approximately 6.099% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $80.07 million.
